All patients were heterozygous FH and the majority of patients had a genetic variant on LDLR; furthermore, more patients were on rosuvastatin 20 mg than atorvastatin 40 mg and 40.0% of patients were on antihypertensive medication. This evidence concerns the gene LDLR and familial hyperaldosteronism.